[Edaily Reporter Lee Hye-ra] On the 8th, iM Securities projected that #Humedics could achieve record-breaking earnings this year, driven by the high growth of its skin booster "Elavie Litio" and the recovery of its filler business.
Jang Ho, an analyst at iM Securities, stated in a report released that day, “We expect filler sales to recover due to the impact of sales growth and improved profitability of Ellavie Litou,” adding, “It is possible to achieve record-breaking earnings this year.”
Analyst Jang identified Ellavie Litio as the company’s core growth driver. He noted, “Since its launch last November, the product has rapidly gained traction, particularly among dermatology and aesthetic clinics nationwide, recording sales of 9.6 billion won last year.” He projected, “First-quarter sales rose to 6 billion won, and annual sales are expected to exceed 35 billion won.”
Analyst Jang explained, “This year, sales of Ellavie Litou are expected to reach over 35 billion won, a 264.6% increase year-over-year,” adding, “As the burden of initial marketing costs, which rose last year, eases, profitability is also expected to improve at an accelerated pace.”
He also predicted that the filler business, which had previously seen a slowdown in growth, would enter a recovery phase. He explained that in the domestic market, the effect of bundled sales—offering both fillers and Litou—is becoming evident, while overseas, the diversification of export regions is gaining momentum through entry into new markets such as Russia and Thailand. Researcher Jang stated, “Domestic sales will see a recovery starting in the second quarter due to the bundled sales effect, while exports will benefit from regional diversification following the acquisition of product approvals in Russia and Thailand.”
Analyst Jang projected Humedics’ consolidated revenue for this year at 198.6 billion won and operating profit at 48.8 billion won. These figures represent year-over-year increases of 16.7% and 15.4%, respectively, marking all-time highs.